DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and Neck

Phase 2

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: Pemetrexed

First Posted Date: 2011-04-12

Last Posted Date: 2013-03-05

Lead Sponsor: Fudan University

Target Recruit Count: 32

Registration Number: NCT01333696

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma

Phase 2

Conditions: Hodgkin Lymphoma

Interventions: Drug: IGEV

First Posted Date: 2011-04-12

Last Posted Date: 2013-03-05

Lead Sponsor: Fudan University

Target Recruit Count: 43

Registration Number: NCT01333605

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Study of Cetuximab in Combination With mFOLFOX-6 (Oxaliplatin, Leucovorin, 5-FU) to Treat Colorectal Liver Metastatic Cancer Patients

Phase 2

Conditions: Colorectal Cancer
Liver Metastases

First Posted Date: 2011-03-24

Last Posted Date: 2011-08-12

Lead Sponsor: Fudan University

Target Recruit Count: 90

Registration Number: NCT01322178

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: irinotecan, capecitabine

First Posted Date: 2011-03-24

Last Posted Date: 2013-06-11

Lead Sponsor: Fudan University

Target Recruit Count: 52

Registration Number: NCT01322152

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy

Phase 3

Completed

Conditions: Primary Breast Cancer

Interventions: Drug: Docetaxel Cyclophosphamide
Drug: Cyclophosphamide Fluorouracil Epirubicin Docetaxel
Drug: Epirubicin Cyclophosphamide Paclitaxel

First Posted Date: 2011-03-15

Last Posted Date: 2020-05-19

Lead Sponsor: Fudan University

Target Recruit Count: 1570

Registration Number: NCT01314833

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion

Phase 4

Conditions: Image Changes of Lumbar Fusion
Bone Turnover Markers
Bone Mineral Density

Interventions: Drug: zoledronic acid
Drug: sodium chloride

First Posted Date: 2011-03-08

Last Posted Date: 2011-03-08

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT01310465

Locations: 🇨🇳
Zhongshan hospital of Fudan university, Shanghai, Shanghai, China

Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer

Phase 1

Conditions: Colorectal Neoplasm

Interventions: Drug: recombinant human endostatin (Endostat)

First Posted Date: 2011-03-08

Last Posted Date: 2011-03-08

Lead Sponsor: Fudan University

Target Recruit Count: 15

Registration Number: NCT01310478

Locations: 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China

Study on Liver Fat Content and Visceral Fat Mass in Overweight and Obese Type 2 Diabetes Patients After Treatment With Basal Insulin

Not Applicable

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: insulin detemir
Drug: neutral protamine insulin

First Posted Date: 2011-03-08

Last Posted Date: 2011-03-08

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT01310452

Locations: 🇨🇳
Zhong Shan Hospital, Fudan University, Shang hai, China

New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases

Phase 3

Completed

Conditions: Neoplasm Metastasis
Colorectal Neoplasms
Liver Neoplasms
Chemotherapy; Maternal, Affecting Fetus

Interventions: Drug: chemotherapy ± targeted therapy

First Posted Date: 2011-03-03

Last Posted Date: 2022-06-14

Lead Sponsor: Fudan University

Target Recruit Count: 320

Registration Number: NCT01307878

Locations: 🇨🇳
Zhongshan hospital, Fudan university, Shanghai, Shanghai, China

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Gemcitabine,cisplatin
Drug: Gemcitabine, Paclitaxel

First Posted Date: 2011-02-01

Last Posted Date: 2015-03-23

Lead Sponsor: Fudan University

Target Recruit Count: 240

Registration Number: NCT01287624

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy